Paenialvin A–D, four peptide antibiotics produced by Paenibacillus alvei DSM 29

Article metrics


Four peptide antibiotics, named paenialvin A–D, were isolated from Paenibacillus alvei DSM 29. Mass spectrum analysis determined the molecular masses of paenialvin A–D to be 1891, 1875, 1877, and 1923 Da, respectively. Tandem mass spectra and nuclear magnetic resonance (NMR) were used to elucidate their chemical structures. Paenialvin A–D showed antimicrobial activity against most strains that were tested, including methicillin-resistant Staphalococcus aureus, Staphylococcus aureus, Bacillus subtilis, Loktanella hongkongensis, Escherichia coli, and Pseudomonas aeruginosa. In particular, the minimum inhibitory concentration of paenialvins against Staphalococcus aureus reached 0.8–3.2 μg/mL. Although they were cytotoxic against HeLa cells at a concentration of 50 μg/mL, the lack of hemolysis by paenialvins confirmed that they are potential candidates for anti-tumor drugs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Levy SB. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother. 2002;49:25–30.

  2. 2.

    Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem. 2009;78:119–46.

  3. 3.

    Levy SB. The challenge of antibiotic resistance. Sci Am. 1998;278:32–39.

  4. 4.

    Guo Y, Huang E, Yuan C, Zhang L, Yousef AE. Isolation of a Paenibacillus sp. strain and structural elucidation of its broad-spectrum lipopeptide antibiotic. Appl Environ Microbiol. 2012;78:3156–65.

  5. 5.

    Saha P, et al. Paenibacillus assamensis sp. nov., a novel bacterium isolated from a warm spring in Assam, India. Int J Syst Evol Microbiol. 2005;55:2577–81.

  6. 6.

    Wu XC, et al. Paenimacrolidin, a novel macrolide antibiotic from Paenibacillus sp. F6‐B70 active against methicillin‐resistant Staphylococcus aureus. Microb Biotechnol. 2011;4:491–502.

  7. 7.

    Ash C, Priest FG, Collins MD. Molecular identification of rRNA group 3 bacilli (Ash, Farrow, Wallbanks and Collins) using a PCR probe test. Antonie Van Leeuwenhoek. 1993;64:253–60.

  8. 8.

    Shida O, Takagi H, Kadowaki K, Nakamura LK, Komagata K. Transfer of Bacillus alginolyticus, Bacillus chondroitinus, Bacillus curdlanolyticus, Bacillus glucanolyticus, Bacillus kobensis, and Bacillus thiaminolyticus to the genus Paenibacillus and emended description of the genus Paenibacillus. Int J Syst Evol Microbiol. 1997;47:289–98.

  9. 9.

    Li J, Beatty PK, Shah S, Jensen SE. Use of PCR-targeted mutagenesis to disrupt production of fusaricidin-type antifungal antibiotics in Paenibacillus polymyxa. Appl Environ Microbiol. 2007;73:3480–9.

  10. 10.

    He Z, et al. Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. Appl Environ Microbiol. 2007;73:168–78.

  11. 11.

    Martin NI, et al. Isolation, structural characterization, and properties of mattacin (Polymyxin M), a cyclic peptide antibiotic produced by Paenibacillus kobensis M. J Biol Chem. 2003;278:13124–32.

  12. 12.

    Wu X-C, et al. Isolation and partial characterization of antibiotics produced by Paenibacillus elgii B69. FEMS Microbiol Lett. 2010;310:32–38.

  13. 13.

    Shaheen M, Li J, Ross AC, Vederas JC, Jensen SE. Paenibacillus polymyxa PKB1 produces variants of polymyxin B-type antibiotics. Chem Biol. 2011;18:1640–8.

  14. 14.

    Kajimura Y, Kaneda M. Fusaricidin A, a new depsipeptide antibiotic produced by Bacillus polymyxa KT-8. J Antibiot. 1996;49:129–35.

  15. 15.

    Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977;46:723–63.

  16. 16.

    Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–41.

  17. 17.

    Djukic M, Becker D, Poehlein A, Voget S, Daniel R. Genome sequence of Paenibacillus alvei DSM 29, a secondary invader during European foulbrood outbreaks. J Bacteriol. 2012;194:6365–6365.

  18. 18.

    Bhushan R, Brückner H. Use of Marfey’s reagent and analogs for chiral amino acid analysis: assessment and applications to natural products and biological systems. J Chromatogr B. 2011;879:3148–61.

  19. 19.

    Fujii K, Shimoya T, Ikai Y, Oka H, Harada K. Further application of advanced Marfey’s method for determination of absolute configuration of primary amino compound. Tetrahedron Lett. 1998;39:2579–82.

  20. 20.

    Li Z-R, et al. Divergent biosynthesis yields a cytotoxic aminomalonate-containing precolibactin. Nat Chem Biol. 2016;12:773–775.

  21. 21.

    Schmitz F-J, et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998;42:807–10.

  22. 22.

    Liu L-L, et al. Four new antibacterial xanthones from the marine-derived actinomycetes Streptomyces caelestis. Mar Drugs. 2012;10:2571–83.

  23. 23.

    Ling LL, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517:455–9.

  24. 24.

    Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000;44:3317–21.

Download references


The authors would like to thank Dr. Kai-Ling Wang for performing the NMR experiment in Shenzhen University. The work was supported by NSFC grant (#41576140) and COMRA grant (COMRRDA17SC01) to P.Y.Q.

Author information

Correspondence to Pei-Yuan Qian.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading